1. Rosenblat, JD, Kakar, R, McIntyre, RS. The cognitive effects of antidepressants in major depressive disorder: A systematic review and meta-analysis of randomized clinical trials. International Journal of Neuropsychopharmacology. 2015; 19(2).
2. Kessler, RC, Akiskal, HS, Ames, M, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. Workers. Am J Psychiatry. 2006; 163(9): 1561–1568.
3. Patten, SB, Williams, JV, Lavorato, DH, et al. Descriptive epidemiology of major depressive disorder in Canada in 2012. Can J Psychiatry. 2015; 60(1): 23–30.
4. Lam, RW, McIntosh, D, Wang, J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 1. Disease burden and principles of care. Can J Psychiatry. 2016; 61(9): 510–523.
5. Ostergaard, SD, Jensen, SO, Bech, P. The heterogeneity of the depressive syndrome: when numbers get serious. Acta Psychiatr Scand. 2011; 124(6): 495–496.
6. McIntyre, RS, Cha, DS, Soczynska, JK, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013; 30(6): 515–527.
7. Evans, VC, Iverson, GL, Yatham, LN, et al. The relationship between neurocognitive and psychosocial functioning in major depressive disorder: a systematic review. J Clin Psychiatry. 2014; 75(12): 1359–1370.
8. McIntyre, RS, Soczynska, JZ, Woldeyohannes, HO, et al. The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project. Compr Psychiatry. 2015; 56: 279–282.
10. Rizvi, SJ, Cyriac, A, Grima, E, et al. Depression and employment status in primary and tertiary care settings. Can J Psychiatry. 2015; 60(1): 14–22.
11. Evans-Lacko, S, Knapp, M. Global patterns of workplace productivity for people with depression: absenteeism and presenteeism costs across eight diverse countries. Soc Psychiatry Psychiatr Epidemiol. 2016; 51(11): 1525–1537.
12. Greenberg, PE, Fournier, AA, Sisitsky, T, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015; 76(2): 155–162.
13. Veiel, HO. A preliminary profile of neuropsychological deficits associated with major depression. J Clin Exp Neuropsychol. 1997; 19(4): 587–603.
14. Goeldner, C, Ballard, TM, Knoflach, F, et al. Cognitive impairment in major depression and the mglu2 receptor as a therapeutic target. Neuropharmacology. 2013; 64: 337–346.
15. Lee, RS, Hermens, DF, Porter, MA, et al. A meta-analysis of cognitive deficits in first-episode major depressive disorder. J Affect Disord. 2012; 140(2): 113–124.
16. Hasselbalch, BJ, Knorr, U, Kessing, LV. Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review. J Affect Disord. 2011; 134(1–3): 20–31.
17. Weisenbach, SL, Boore, LA, Kales, HC. Depression and cognitive impairment in older adults. Curr Psychiatry Rep. 2012; 14(4): 280–288.
18. Buist-Bouwman, MA, Ormel, J, de Graaf, R, et al. Mediators of the association between depression and role functioning. Acta Psychiatr Scand. 2008; 118(6): 451–458.
19. Jaeger, J, Berns, S, Uzelac, S, et al. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006; 145(1): 39–48.
20. Southerland, G, Stonebridge, C. Healthy Brains at Work: Estimating the Impact of Workplace Mental Health Benefits and Programs. Ottawa: The Conference Board of Canada; 2016.
21. Kennedy, SH, Lam, RW, McIntyre, RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological treatments. Can J Psychiatry. 2016; 61(9): 540–560.
22. McIntyre, RS, Lee, Y, Mansur, RB. Treating to target in major depressive disorder: response to remission to functional recovery. CNS Spectr. 2015; 20(Suppl 1): 20–30; quiz 31.
23. Campbell, S, Macqueen, G. The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci. 2004; 29(6): 417–426.
24. Murrough, JW, Iacoviello, B, Neumeister, A, et al. Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies. Neurobiol Learn Mem. 2011; 96(4): 553–563.
25. Harmer, CJ, Clark, L, Grayson, L, et al. Sustained attention deficit in bipolar disorder is not a working memory impairment in disguise. Neuropsychologia. 2002; 40(9): 1586–1590.
26. Iosifescu, DV. The relation between mood, cognition and psychosocial functioning in psychiatric disorders. Eur Neuropsychopharmacol. 2012; 22(Suppl 3): S499–S504.
27. Fried, EI, Nesse, RM. The impact of individual depressive symptoms on impairment of psychosocial functioning. PLoS One. 2014; 9(2): e90311.
28. Kim, JM, Chalem, Y, di Nicola, S, et al. A cross-sectional study of functional disabilities and perceived cognitive dysfunction in patients with major depressive disorder in South Korea: the PERFORM-K study. Psychiatry Res. 2016; 239: 353–361.
29. Francomano, A, Bonanno, B, Fuca, L, et al. The role of antidepressant treatments on cognitive deficits. A review of recent literature. Clinical Neuropsychiatry. 2011; 8(6): 354–366.
30. Garnock-Jones, KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs. 2014; 28(9): 855–874.
31. Thase, ME, Mahableshwarkar, AR, Dragheim, M, et al. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol. 2016; 26(6): 979–993.
32. Katona, C, Hansen, T, Olsen, CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of lu aa21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012; 27(4): 215–223.
33. Harrison, JE, Lophaven, S, Olsen, CK. Which cognitive domains are improved by treatment with vortioxetine? International Journal of Neuropsychopharmacology. 2016.
34. McIntyre, RS, Lophaven, S, Olsen, CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. International Journal of Neuropsychopharmacology. 2014; 17(10): 1557–1567.
35. McIntyre, RS, Florea, I, Tonnoir, B, et al. Efficacy of vortioxetine on cognitive functioning in working patients with major depressive disorder. J Clin Psychiatry. 2017; 78(1): 115–121.
36. Mahableshwarkar, AR, Zajecka, J, Jacobson, W, et al. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology. 2015; 40(8): 2025–2037.
37. Trintellix(tm) (vortioxetine) product monograph. Montreal, QC, Canada: Lundbeck Canada Inc.; 2014.
38. Boulenger, JP, Loft, H, Olsen, CK. Efficacy and safety of vortioxetine (lu aa21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014; 29(3): 138–149.
39. Henigsberg, N, Mahableshwarkar, AR, Jacobsen, P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of lu aa21004 in adults with major depressive disorder. J Clin Psychiatry. 2012; 73(7): 953–959.
40. Jha, MK, Minhajuddin, A, Greer, TL, et al. Early improvement in work productivity predicts future clinical course in depressed outpatients: findings from the CO-MED trial. Am J Psychiatry. 2016; 173(12): 1196–1204.
41. Srisurapanont, M, Suttajit, S, Eurviriyanukul, K, et al. Discrepancy between objective and subjective cognition in adults with major depressive disorder. Scientific Reports. 2017; 7(1): 3901.
42. Lam, RW, Iverson, GL, Evans, VC, et al. The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder. J Affect Disord. 2016; 203: 55–61.
43. Cha, DS, Carmona, NE, Subramaniapillai, M, et al. Cognitive impairment as measured by the thinc-integrated tool (thinc-it): Association with psychosocial function in major depressive disorder. J Affect Disord. 2017; 222: 14–20.
44. Hudson, JI, Perahia, DG, Gilaberte, I, et al. Duloxetine in the treatment of major depressive disorder: an open-label study. BMC Psychiatry. 2007; 7: 43.
45. Wohlreich, MM, Martinez, JM, Mallinckrodt, CH, et al. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. Journal of Clinical Psychopharmacology. 2005; 25(6): 552–560.
46. Lawrence, C, Roy, A, Harikrishnan, V, et al. Association between severity of depression and self-perceived cognitive difficulties among full-time employees. Prim Care Companion CNS Disord. 2013; 15(3).
47. Lam, RW, Saragoussi, D, Danchenko, N, et al. Psychometric validation of Perceived Deficits Questionnaire–Depression (PDQ-D) in patients with major depressive disorder (MDD). Value in Health. 2013; 16(7): A330.
48. Lerner, D, Adler, DA, Chang, H, et al. The clinical and occupational correlates of work productivity loss among employed patients with depression. J Occup Environ Med. 2004; 46(6 Suppl): S46–S55.
49. Tang, K, Beaton, DE, Boonen, A, et al. Measures of work disability and productivity: Rheumatoid Arthritis Specific Work Productivity Survey (WPS-RA), Workplace Activity Limitations Scale (WALS), Work Instability Scale for Rheumatoid Arthritis (RA-WIS), Work Limitations Questionnaire (WLQ), and Work Productivity and Activity Impairment Questionnaire (WPAI). Arthritis Care Res (Hoboken). 2011; 63(Suppl 11): S337–S349.
50. Rush, AJ, Trivedi, MH, Ibrahim, HM, et al. The 16-item Quick Inventory Of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003; 54(5): 573–583.
51. Ustun, TB, Chatterji, S, Kostanjsek, N, et al. Developing the World Health Organization Disability Assessment Schedule 2.0. Bulletin of the World Health Organization. 2010; 88(11): 815–823.
52. Reilly, MC, Zbrozek, AS, Dukes, EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993; 4(5): 353–365.
53. Trivedi, MH, Morris, DW, Wisniewski, SR, et al. Increase in work productivity of depressed individuals with improvement in depressive symptom severity. Am J Psychiatry. 2013; 170(6): 633–641.
54. Arbuckle, R, Frye, MA, Brecher, M, et al. The psychometric validation of the Sheehan Disability Scale (SDS) in patients with bipolar disorder. Psychiatry Res. 2009; 165(1–2): 163–174.
55. Lowe, B, Decker, O, Muller, S, et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care. 2008; 46(3): 266–274.
56. Guy, W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; 2014.
57. Swan, GE, Carmelli, D, LaRue, A. Performance on the Digit Symbol Substitution Test and 5-year mortality in the western collaborative group study. Am J Epidemiol. 1995; 141(1): 32–40.
58. Rosano, C, Newman, AB, Katz, R, et al. Association between lower Digit Symbol Substitution Test score and slower gait and greater risk of mortality and of developing incident disability in well-functioning older adults. J Am Geriatr Soc. 2008; 56(9): 1618–1625.